Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTIC CTI BioPharma	$9.09	$9.06	$4.01 ▼ $9.10	$1.20B	0.83	4.50 million shs	N/A
PBH Prestige Consumer Healthcare	$86.58 +1.8%	$83.52	$63.79 ▼ $90.04	$4.27B	0.45	298,503 shs	240,067 shs
RYTM Rhythm Pharmaceuticals	$67.80 -0.5%	$61.10	$38.90 ▼ $69.89	$4.26B	2.3	555,019 shs	595,338 shs
SRPT Sarepta Therapeutics	$40.14 +1.1%	$47.54	$34.10 ▼ $173.25	$3.96B	0.61	1.77 million shs	52,696 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTIC CTI BioPharma	0.00%	0.00%	0.00%	0.00%	0.00%
PBH Prestige Consumer Healthcare	+0.71%	+0.23%	-2.22%	+0.63%	+30.97%
RYTM Rhythm Pharmaceuticals	-2.04%	+4.81%	+16.30%	+33.28%	+66.93%
SRPT Sarepta Therapeutics	-7.67%	+5.22%	+9.48%	-60.57%	-67.80%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTIC CTI BioPharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PBH Prestige Consumer Healthcare	3.7741 of 5 stars	1.3	2.0	1.7	3.5	3.5	2.5	1.9
RYTM Rhythm Pharmaceuticals	3.7139 of 5 stars	3.5	1.0	0.0	4.3	2.5	0.8	0.6
SRPT Sarepta Therapeutics	4.8397 of 5 stars	4.4	2.0	0.0	4.2	3.1	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTIC CTI BioPharma	0.00	N/A	N/A	N/A
PBH Prestige Consumer Healthcare	2.50	Moderate Buy	$93.33	7.81% Upside
RYTM Rhythm Pharmaceuticals	3.00	Buy	$76.62	13.00% Upside
SRPT Sarepta Therapeutics	2.87	Moderate Buy	$122.61	205.47% Upside

Current Analyst Ratings Breakdown

Latest CTIC, PBH, RYTM, and SRPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/6/2025	SRPT Sarepta Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sector Perform ➝ Sector Outperform	$80.00
5/29/2025	RYTM Rhythm Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$78.00 ➝ $94.00
5/22/2025	SRPT Sarepta Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$40.00 ➝ $40.00
5/20/2025	SRPT Sarepta Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$169.00 ➝ $84.00
5/8/2025	PBH Prestige Consumer Healthcare	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
5/8/2025	SRPT Sarepta Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy	$188.00 ➝ $85.00
5/8/2025	SRPT Sarepta Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$115.00 ➝ $100.00
5/8/2025	SRPT Sarepta Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Inline	$50.00
5/7/2025	RYTM Rhythm Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$66.00 ➝ $72.00
5/7/2025	SRPT Sarepta Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$87.00 ➝ $58.00
5/7/2025	SRPT Sarepta Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$178.00 ➝ $100.00

(Data available from 6/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTIC CTI BioPharma	$53M	22.62	N/A	N/A	($0.14) per share	-64.93
PBH Prestige Consumer Healthcare	$1.14B	3.76	$5.08 per share	17.03	$36.10 per share	2.40
RYTM Rhythm Pharmaceuticals	$136.86M	31.52	N/A	N/A	$2.87 per share	23.62
SRPT Sarepta Therapeutics	$2.23B	1.77	N/A	N/A	$9.19 per share	4.37

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTIC CTI BioPharma	-$92.99M	-$0.58	N/A	26.74	N/A	-91.38%	N/A	-55.82%	N/A
PBH Prestige Consumer Healthcare	$209.34M	$4.29	20.24	18.19	2.69	19.13%	12.36%	6.39%	8/6/2025 (Estimated)
RYTM Rhythm Pharmaceuticals	-$184.68M	-$2.81	N/A	N/A	N/A	-230.07%	-367.36%	-77.47%	8/5/2025 (Estimated)
SRPT Sarepta Therapeutics	-$535.98M	-$2.69	32.20	3.67	N/A	7.43%	11.00%	3.35%	8/6/2025 (Estimated)

Latest CTIC, PBH, RYTM, and SRPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q4 2025	PBH Prestige Consumer Healthcare	$1.30	$1.32	+$0.02	$1.00	$289.36 million	$296.52 million
5/7/2025	Q1 2025	RYTM Rhythm Pharmaceuticals	-$0.69	-$0.81	-$0.12	-$0.81	$40.43 million	$37.72 million
5/6/2025	Q1 2025	SRPT Sarepta Therapeutics	$2.20	-$3.42	-$5.62	-$4.60	$685.75 million	$744.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTIC CTI BioPharma	N/A	N/A	N/A	N/A	N/A
PBH Prestige Consumer Healthcare	$1.90	2.19%	N/A	44.29%	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTIC CTI BioPharma	N/A	1.27	1.26
PBH Prestige Consumer Healthcare	0.56	3.68	2.20
RYTM Rhythm Pharmaceuticals	N/A	3.49	3.34
SRPT Sarepta Therapeutics	0.93	3.84	3.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTIC CTI BioPharma	91.45%
PBH Prestige Consumer Healthcare	99.95%
RYTM Rhythm Pharmaceuticals	N/A
SRPT Sarepta Therapeutics	86.68%

Insider Ownership

Company	Insider Ownership
CTIC CTI BioPharma	7.61%
PBH Prestige Consumer Healthcare	1.60%
RYTM Rhythm Pharmaceuticals	6.10%
SRPT Sarepta Therapeutics	7.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTIC CTI BioPharma	127	131.88 million	121.84 million	Optionable
PBH Prestige Consumer Healthcare	540	49.42 million	48.75 million	Optionable
RYTM Rhythm Pharmaceuticals	140	63.62 million	58.02 million	Optionable
SRPT Sarepta Therapeutics	840	98.28 million	88.17 million	Optionable

CTIC, PBH, RYTM, and SRPT Headlines

Recent News About These Companies

1 Unprofitable Stock for Long-Term Investors and 2 to Ignore

June 10 at 7:33 AM | uk.finance.yahoo.com

Sarepta Therapeutics (NASDAQ:SRPT) Trading Down 6.1% - Should You Sell?

June 9 at 1:39 PM | marketbeat.com

Sarepta Therapeutics (NASDAQ:SRPT) Upgraded to Sector Outperform at Scotiabank

June 9 at 1:38 AM | americanbankingnews.com

BMO Capital Remains a Buy on Sarepta Therapeutics (SRPT)

June 8 at 7:19 PM | theglobeandmail.com

Sarepta Therapeutics (NasdaqGS:SRPT) Gains 19% Over Past Month Following Japan Approval

June 8 at 7:19 PM | finance.yahoo.com

Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 8% - Should You Buy?

June 8 at 3:51 AM | americanbankingnews.com

July 25th Options Now Available For Sarepta Therapeutics (SRPT)

June 7 at 10:21 PM | nasdaq.com

Sarepta Therapeutics’ gene therapy to treat limb girdle muscular dystrophy type 2E/R4 gets US FDA platform technology designation

June 7 at 1:26 AM | pharmabiz.com

Sarepta upgraded at Scotiabank on attractive risk reward setup

June 7 at 1:26 AM | msn.com

Scotiabank Upgrades Sarepta Therapeutics (SRPT)

June 7 at 1:26 AM | msn.com

Sarepta Therapeutics Approves Amendments at Annual Meeting

June 6, 2025 | tipranks.com

Sarepta Therapeutics (NASDAQ:SRPT) Trading Up 8% - Here's Why

June 6, 2025 | marketbeat.com

Sarepta Therapeutics (SRPT) Upgraded by Scotiabank with Sector Outperform Rating | SRPT Stock News

June 6, 2025 | gurufocus.com

Scotiabank Upgrades Sarepta Therapeutics (NASDAQ:SRPT) to "Sector Outperform"

June 6, 2025 | marketbeat.com

Sarepta Wins FDA’s Platform Technology Designation, Marking ‘Critical Shift’ in Gene Therapy Development

June 6, 2025 | biospace.com

FDA grants Platform designation for Sarepta’s SRP-9003

June 6, 2025 | thepharmaletter.com

The FDA granted Sarepta’s rAAVrh74 Viral Vector a Platform Technology Designation

June 5, 2025 | insidermonkey.com

Why Is Sarepta Therapeutics (SRPT) Up 7.7% Since Last Earnings Report?

June 5, 2025 | zacks.com

FDA Grants Platform Technology Tag to Sarepta's Gene Therapy Vector

June 5, 2025 | zacks.com

FDA to use new review tool on Sarepta’s gene therapy work

June 4, 2025 | biopharmadive.com

Buy Rating on Sarepta Therapeutics Driven by FDA Platform Technology Designation

June 4, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTIC, PBH, RYTM, and SRPT Company Descriptions

CTI BioPharma NASDAQ:CTIC

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.

Prestige Consumer Healthcare NYSE:PBH

$86.58 +1.52 (+1.78%)

As of 09:43 AM Eastern

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Rhythm Pharmaceuticals NASDAQ:RYTM

$67.80 -0.31 (-0.46%)

As of 09:44 AM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Sarepta Therapeutics NASDAQ:SRPT

$40.14 +0.43 (+1.08%)

As of 09:44 AM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time